Search

Your search keyword '"van Roozendaal CEP"' showing total 4 results
Start Over Author "van Roozendaal CEP" Publication Year Range Last 50 years
4 results on '"van Roozendaal CEP"'

1. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers

Author

Antoniou, AC, Sinilnikova, OM, McGuffog, L, Healey, S, Nevanlinna, H, Heikkinen, T, Simard, J, Spurdle, AB, Beesley, J, Chen, XQ, Neuhausen, SL, Ding, YC, Couch, FJ, Wang, XS, Fredericksen, Z, Peterlongo, P, Peissel, B, Bonanni, B, Viel, A, Bernard, L, Radice, P, Szabo, CI, Foretova, L, Zikan, M, Claes, K, Greene, MH, Mai, PL, Rennert, G, Lejbkowicz, F, Andrulis, IL, Ozcelik, H, Glendon, G, Gerdes, AM, Thomassen, M, Sunde, L, Caligo, MA, Laitman, Y, Kontorovich, T, Cohen, S, Kaufman, B, Dagan, E, Baruch, RG, Friedman, E, Harbst, K, Barbany-Bustinza, G, Rantala, J, Ehrencrona, H, Karlsson, P, Domchek, SM, Nathanson, KL, Osorio, A, Blanco, I, Lasa, A, Benitez, J, Hamann, U, Hogervorst, FBL, Rookus, MA, Collee, JM, Devilee, P, Ligtenberg, MJ, van der Luijt, RB, Aalfs, CM, Waisfisz, Q, Wijnen, J, van Roozendaal, CEP, Peock, S, Cook, M, Frost, D, Oliver, C, Platte, R, Evans, DG, Lalloo, F, Eeles, R, Izatt, L, Davidson, R, Chu, C, Eccles, D, Cole, T, Hodgson, S, Godwin, AK, Stoppa-Lyonnet, D, Buecher, B, Leone, M, Bressac-de Paillerets, B, Remenieras, A, Caron, O, Lenoir, GM, Sevenet, N, Longy, M, Ferrer, SF, Prieur, F, Goldgar, D, Miron, A, John, EM, Buys, SS, Daly, MB, Hopper, JL, Terry, MB, Yassin, Y, Singer, C, Gschwantler-Kaulich, D, Staudigl, C, Hansen, TVO, Barkardottir, RB, Kirchhoff, T, Pal, P, Kosarin, K, Offit, K, Piedmonte, M, Rodriguez, GC, Wakeley, K, Boggess, JF, Basil, J, Schwartz, PE, Blank, SV, Toland, AE, Montagna, M, Casella, C, Imyanitov, EN, Allavena, A, Schmutzler, RK, Versmold, B, Engel, C, Meindl, A, Ditsch, N, Arnold, N, Niederacher, D, Deissler, H, Fiebig, B, Suttner, C, Schonbuchner, I, Gadzicki, D, Caldes, T, de la Hoya, M, Pooley, KA, Easton, DF, and Chenevix-Trench, G

Abstract

Genome-wide association studies of breast cancer have identified multiple single nucleotide polymorphisms (SNPs) that are associated with increased breast cancer risks in the general population. In a previous study, we demonstrated that the minor alleles at three of these SNPs, in FGFR2, TNRC9 and MAP3K1, also confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers. Three additional SNPs rs3817198 at LSP1, rs13387042 at 2q35 and rs13281615 at 8q24 have since been reported to be associated with breast cancer in the general population, and in this study we evaluated their association with breast cancer risk in 9442 BRCA1 and 5665 BRCA2 mutation carriers from 33 study centres. The minor allele of rs3817198 was associated with increased breast cancer risk only for BRCA2 mutation carriers [hazard ratio (HR) = 1.16, 95% CI: 1.07-1.25, P-trend = 2.8 x 10(-4)]. The best fit for the association of SNP rs13387042 at 2q35 with breast cancer risk was a dominant model for both BRCA1 and BRCA2 mutation carriers (BRCA1: HR = 1.14, 95% CI: 1.04-1.25, P = 0.0047; BRCA2: HR = 1.18 95% CI: 1.04-1.33, P = 0.0079). SNP rs13281615 at 8q24 was not associated with breast cancer for either BRCA1 or BRCA2 mutation carriers, but the estimated association for BRCA2 mutation carriers (per-allele HR = 1.06, 95% CI: 0.98-1.14) was consistent with odds ratio estimates derived from population-based case-control studies. The LSP1 and 2q35 SNPs appear to interact multiplicatively on breast cancer risk for BRCA2 mutation carriers. There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not.

Published
2009

2. Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer

Author

Ashworth, A, Maxwell, CA, Benitez, J, Gomez-Baldo, L, Osorio, A, Bonifaci, N, Fernandez-Ramires, R, Costes, SV, Guino, E, Chen, H, Evans, GJR, Mohan, P, Catala, I, Petit, A, Aguilar, H, Villanueva, A, Aytes, A, Serra-Musach, J, Rennert, G, Lejbkowicz, F, Peterlongo, P, Manoukian, S, Peissel, B, Ripamonti, CB, Bonanni, B, Viel, A, Allavena, A, Bernard, L, Radice, P, Friedman, E, Kaufman, B, Laitman, Y, Dubrovsky, M, Milgrom, R, Jakubowska, A, Cybulski, C, Gorski, B, Jaworska, K, Durda, K, Sukiennicki, G, Lubinski, J, Shugart, YY, Domchek, SM, Letrero, R, Weber, BL, Hogervorst, FBL, Rookus, MA, Collee, JM, Devilee, P, Ligtenberg, MJ, van der Luijt, RB, Aalfs, CM, Waisfisz, Q, Wijnen, J, van Roozendaal, CEP, Easton, DF, Peock, S, Cook, M, Oliver, C, Frost, D, Harrington, P, Evans, DG, Lalloo, F, Eeles, R, Izatt, L, Chu, C, Eccles, D, Douglas, F, Brewer, C, Nevanlinna, H, Heikkinen, T, Couch, FJ, Lindor, NM, Wang, X, Godwin, AK, Caligo, MA, Lombardi, G, Loman, N, Karlsson, P, Ehrencrona, H, von Wachenfeldt, A, Barkardottir, RB, Hamann, U, Rashid, MU, Lasa, A, Caldes, T, Andres, R, Schmitt, M, Assmann, V, Stevens, K, Offit, K, Curado, J, Tilgner, H, Guigo, R, Aiza, G, Brunet, J, Castellsague, J, Martrat, G, Urruticoechea, A, Blanco, I, Tihomirova, L, Goldgar, DE, Buys, S, John, EM, Miron, A, Southey, M, Daly, MB, Schmutzler, RK, Wappenschmidt, B, Meindl, A, Arnold, N, Deissler, H, Varon-Mateeva, R, Sutter, C, Niederacher, D, Imyamitov, E, Sinilnikova, OM, Stoppa-Lyonne, D, Mazoyer, S, Verny-Pierre, C, Castera, L, de Pauw, A, Bignon, Y-J, Uhrhammer, N, Peyrat, J-P, Vennin, P, Ferrer, SF, Collonge-Rame, M-A, Mortemousque, I, Spurdle, AB, Beesley, J, Chen, X, Healey, S, Barcellos-Hoff, MH, Vidal, M, Gruber, SB, Lazaro, C, Capella, G, McGuffog, L, Nathanson, KL, Antoniou, AC, Chenevix-Trench, G, Fleisch, MC, Moreno, V, Angel Pujana, M, Ashworth, A, Maxwell, CA, Benitez, J, Gomez-Baldo, L, Osorio, A, Bonifaci, N, Fernandez-Ramires, R, Costes, SV, Guino, E, Chen, H, Evans, GJR, Mohan, P, Catala, I, Petit, A, Aguilar, H, Villanueva, A, Aytes, A, Serra-Musach, J, Rennert, G, Lejbkowicz, F, Peterlongo, P, Manoukian, S, Peissel, B, Ripamonti, CB, Bonanni, B, Viel, A, Allavena, A, Bernard, L, Radice, P, Friedman, E, Kaufman, B, Laitman, Y, Dubrovsky, M, Milgrom, R, Jakubowska, A, Cybulski, C, Gorski, B, Jaworska, K, Durda, K, Sukiennicki, G, Lubinski, J, Shugart, YY, Domchek, SM, Letrero, R, Weber, BL, Hogervorst, FBL, Rookus, MA, Collee, JM, Devilee, P, Ligtenberg, MJ, van der Luijt, RB, Aalfs, CM, Waisfisz, Q, Wijnen, J, van Roozendaal, CEP, Easton, DF, Peock, S, Cook, M, Oliver, C, Frost, D, Harrington, P, Evans, DG, Lalloo, F, Eeles, R, Izatt, L, Chu, C, Eccles, D, Douglas, F, Brewer, C, Nevanlinna, H, Heikkinen, T, Couch, FJ, Lindor, NM, Wang, X, Godwin, AK, Caligo, MA, Lombardi, G, Loman, N, Karlsson, P, Ehrencrona, H, von Wachenfeldt, A, Barkardottir, RB, Hamann, U, Rashid, MU, Lasa, A, Caldes, T, Andres, R, Schmitt, M, Assmann, V, Stevens, K, Offit, K, Curado, J, Tilgner, H, Guigo, R, Aiza, G, Brunet, J, Castellsague, J, Martrat, G, Urruticoechea, A, Blanco, I, Tihomirova, L, Goldgar, DE, Buys, S, John, EM, Miron, A, Southey, M, Daly, MB, Schmutzler, RK, Wappenschmidt, B, Meindl, A, Arnold, N, Deissler, H, Varon-Mateeva, R, Sutter, C, Niederacher, D, Imyamitov, E, Sinilnikova, OM, Stoppa-Lyonne, D, Mazoyer, S, Verny-Pierre, C, Castera, L, de Pauw, A, Bignon, Y-J, Uhrhammer, N, Peyrat, J-P, Vennin, P, Ferrer, SF, Collonge-Rame, M-A, Mortemousque, I, Spurdle, AB, Beesley, J, Chen, X, Healey, S, Barcellos-Hoff, MH, Vidal, M, Gruber, SB, Lazaro, C, Capella, G, McGuffog, L, Nathanson, KL, Antoniou, AC, Chenevix-Trench, G, Fleisch, MC, Moreno, V, and Angel Pujana, M

Abstract

Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation. However, the function of BRCA1 in this process and its link to carcinogenesis remain unknown. Here we depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer. Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio ((w)HR) = 1.09 (95% CI 1.02-1.16), p(trend) = 0.017; and n = 3,965, (w)HR = 1.04 (95% CI 0.94-1.16), p(trend) = 0.43; respectively. Subsequently, studies of MCF10A apicobasal polarization revealed a central role for BRCA1 and RHAMM, together with AURKA and TPX2, in essential reorganization of microtubules. Mechanistically, reorganization is facilitated by BRCA1 and impaired by AURKA, which is regulated by negative feedback involving RHAMM and TPX2. Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.

Published
2011

4. Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.

Author

Koster R, Brandão RD, Tserpelis D, van Roozendaal CEP, van Oosterhoud CN, Claes KBM, Paulussen ADC, Sinnema M, Vreeburg M, van der Schoot V, Stumpel CTRM, Broen MPG, Spruijt L, Jongmans MCJ, Lesnik Oberstein SAJ, Plomp AS, Misra-Isrie M, Duijkers FA, Louwers MJ, Szklarczyk R, Derks KWJ, Brunner HG, van den Wijngaard A, van Geel M, and Blok MJ

Abstract

Neurofibromatosis type 1 (NF1) is caused by loss-of-function variants in the NF1 gene. Approximately 10% of these variants affect RNA splicing and are either missed by conventional DNA diagnostics or are misinterpreted by in silico splicing predictions. Therefore, a targeted RNAseq-based approach was designed to detect pathogenic RNA splicing and associated pathogenic DNA variants. For this method RNA was extracted from lymphocytes, followed by targeted RNAseq. Next, an in-house developed tool (QURNAs) was used to calculate the enrichment score (ERS) for each splicing event. This method was thoroughly tested using two different patient cohorts with known pathogenic splice-variants in NF1. In both cohorts all 56 normal reference transcript exon splice junctions, 24 previously described and 45 novel non-reference splicing events were detected. Additionally, all expected pathogenic splice-variants were detected. Eleven patients with NF1 symptoms were subsequently tested, three of which have a known NF1 DNA variant with a putative effect on RNA splicing. This effect could be confirmed for all 3. The other eight patients were previously without any molecular confirmation of their NF1-diagnosis. A deep-intronic pathogenic splice variant could now be identified for two of them (25%). These results suggest that targeted RNAseq can be successfully used to detect pathogenic RNA splicing variants in NF1., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results